CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 23 enrolled
Drug / intervention
L-Lysine +1 moredrug
Likely dose
L-Lysine 5gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05210504
NCT05210504Phase 1Completed
CompareCT.gov

Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3

Vanderbilt University Medical Center·interventional·Posted Jan 27, 2022·Updated Jun 5, 2024

In Brief

A Phase 1 clinical trial evaluating L-Lysine and Normal Saline for Diabetes Mellitus, Type 2. Completed, enrolled 23 participants across 1 site.

Detailed Summary

This study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedJan 27, 2022
Enrollment StartMar 9, 2022
Primary CompletionJan 27, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.4 years ago

Interventions

L-Lysinedrug

5g L-lysine in 50ml water, administered orally

Normal Salinedrug

Normal (0.9%) Saline